We are live on ! Find out more
TOVX icon

Theriva Biologics

19 hedge funds and large institutions have $707K invested in Theriva Biologics in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

15% more capital inflows, than outflows

Capital inflows: $175K | Capital outflows: $151K

6% more funds holding

Funds holding: 18 → 19 (+1)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.56% less ownership

Funds ownership: 8.13% → 7.57% (-0.56%)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
2
Closed
6
Calls
$2.67​M
Puts
–
Net Calls
+$2.67​M
Net Calls Change
+$991​K

TOVX Hedge Fund Activity: Q2 2020 in Review

19 of the 4,891 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2020, worth a combined $707K — up 60% from $442K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TOVX positions and 6 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $76.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $79K sold.

  • 19 institutional investors held Theriva Biologics (TOVX) as of Q2 2020, up from 18 in Q1 2020.
  • Funds reported $707K of Theriva Biologics stock for Q2 2020, up 60% quarter-over-quarter.
  • 7 funds opened new Theriva Biologics positions in Q2 2020 and 6 closed out, a net change of +1 holder.
  • The largest Theriva Biologics buyer in Q2 2020 was Renaissance Technologies, an estimated $76.5K added.
  • The largest Theriva Biologics seller in Q2 2020 was Susquehanna International Group, an estimated $79K sold.

Based on aggregated 13F filings for Q2 2020.